AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3 0 27.05.2024 16:40 Fiercebiotech.com AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3 jwaldron Mon, 05/27/2024 - 09:40
